Scarica l'app Stockscreener
11.93
0.25%
-0.03
Dopo l'orario di chiusura:
12.10
0.17
+1.42%
Precedente Chiudi:
$11.96
Aprire:
$11.66
Volume 24 ore:
778.95K
Relative Volume:
0.78
Capitalizzazione di mercato:
$974.29M
Reddito:
$54.55M
Utile/perdita netta:
$-193.57M
Rapporto P/E:
-4.128
EPS:
-2.89
Flusso di cassa netto:
$-181.86M
1 W Prestazione:
-6.65%
1M Prestazione:
+22.61%
6M Prestazione:
-41.14%
1 anno Prestazione:
-28.69%
Intervallo 1D:
$11.62
$12.38
Intervallo di 1 settimana:
$11.62
$13.09
Portata 52W:
$8.18
$29.56
Nurix Therapeutics Inc Stock (NRIX) Company Profile
Nome
Nurix Therapeutics Inc
Settore
Industria
Telefono
(415) 660-5320
Indirizzo
1700 OWENS STREET, SUITE 205, SAN FRANCISCO
Confronta NRIX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
11.93 | 974.29M | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Nurix Therapeutics Inc Stock (NRIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-17 | Iniziato | Leerink Partners | Market Perform |
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-12-06 | Iniziato | BMO Capital Markets | Outperform |
| 2024-10-24 | Iniziato | UBS | Buy |
| 2024-10-11 | Iniziato | Jefferies | Buy |
| 2024-09-06 | Ripresa | Robert W. Baird | Outperform |
| 2024-07-31 | Iniziato | Truist | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-03-09 | Iniziato | Barclays | Overweight |
| 2023-02-28 | Iniziato | Oppenheimer | Outperform |
| 2022-10-11 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-05-31 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | Iniziato | Wells Fargo | Equal Weight |
| 2021-12-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2021-04-30 | Ripresa | Piper Sandler | Overweight |
| 2021-04-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Iniziato | Berenberg | Buy |
| 2020-11-19 | Iniziato | Robert W. Baird | Outperform |
| 2020-08-18 | Iniziato | JP Morgan | Overweight |
| 2020-08-18 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Stifel | Buy |
Mostra tutto
Nurix Therapeutics Inc Borsa (NRIX) Ultime notizie
Nurix Therapeutics (NASDAQ:NRIX) Trading Down 5.9%Here's What Happened - MarketBeat
Nurix Therapeutics’ SWOT analysis: promising BTK degrader stock faces challenges - Investing.com Canada
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | NRIX Stock News - GuruFocus
Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Nurix Therapeutics Expands Team with 17 New Hires, Grants $2.1M in Equity Awards - Stock Titan
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.18 Average PT from Brokerages - MarketBeat
Nurix Therapeutics (NRIX) Shares Dip After Trial Update on Bexob - GuruFocus
Nurix stock drops on new trial data for lead drug (NRIX:NASDAQ) - Seeking Alpha
Transcript : Nurix Therapeutics, Inc.Special Call - marketscreener.com
Nurix Therapeutics Announces Positive Phase 1 Trial Results - TipRanks
NRIX: Promising Data from Nurix's Bexobrutideg Clinical Trial | - GuruFocus
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chroni - GuruFocus
Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenströ - Yahoo Finance
Nurix Therapeutics, Inc. to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg Being Presented At the 30Th European Hematology Association Congress - marketscreener.com
Nurix Therapeutics to Host a Webcast Conference Call to Discuss - GuruFocus
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025) - The Manila Times
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congr - GuruFocus
Nurix Therapeutics to Host Webcast on Phase 1 Clinical Trial Data for Bexobrutideg (NX-5948) at EHA2025 - Nasdaq
Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 ... - Bluefield Daily Telegraph
Bexobrutideg Phase 1 Trial Shows Promise in Blood Cancer Treatment at EHA Congress | NRIX Stock News - Stock Titan
Nurix Therapeutics (NASDAQ:NRIX) Shares Gap UpHere's Why - MarketBeat
Stifel Maintains Buy Rating on Nurix (NRIX) Stock - MSN
Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last? - MSN
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Two Sigma Investments LP - MarketBeat
(NRIX) On The My Stocks Page - news.stocktradersdaily.com
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Position Reduced by Nuveen Asset Management LLC - MarketBeat
Sanofi exercises option to license STAT6 program from Nurix collaboration - BioWorld MedTech
Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6 - marketscreener.com
Sanofi Exercises Exclusive License for Nurix Therapeutics' STAT6 Program - marketscreener.com
Sanofi Exercises License Extension Option To Nurix'S Stat6 Program - marketscreener.com
Sanofi Expands Rare Immunology Portfolio With Blueprint Buyout - Benzinga
Sanofi Licenses Nurix's STAT6 Program, Enhancing Drug Collaborat - GuruFocus
Sanofi Licenses Nurix's STAT6 Program, Enhancing Drug Collaboration | NRIX Stock News - GuruFocus
Sanofi Exercises License Extension Option to Nurix's STAT6 Program | NRIX Stock News - GuruFocus
Nurix secures additional $15 million from Sanofi license deal - Investing.com
Nurix Therapeutics Secures $15 Million License Extension from Sanofi for STAT6 Program - Nasdaq
Sanofi Bets Big on Nurix: $465M Deal for Revolutionary Inflammation Drug That Could Transform Asthma Treatment - Stock Titan
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Bought by Wellington Management Group LLP - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Trading Up 3.9%Time to Buy? - MarketBeat
Millennium Management LLC Has $7.99 Million Stock Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Twinbeech Capital LP Sells 35,683 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics to Participate in the Jefferies Global Health - GuruFocus
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference - The Manila Times
Nurix Therapeutics Leadership to Share Latest Protein Degradation Developments at Major Healthcare Conference - Stock Titan
Nurix Therapeutics' SWOT analysis: promising pipeline drives stock outlook - Investing.com Australia
Nurix Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com
Nurix Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com UK
When (NRIX) Moves Investors should Listen - news.stocktradersdaily.com
Velan Capital Investment Management LP Buys New Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Point72 Asset Management L.P. Buys Shares of 872,959 Nurix Therapeutics, Inc. (NASDAQ:NRIX) - MarketBeat
Nurix Therapeutics Inc Azioni (NRIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):